Clinical Trials
9 trialsNCT07488884 2026-04-29
ResQ108B-PANC
ImmunityBio, Inc.
Phase 1 Not yet recruiting
NCT07049432 2026-04-01
CARMEN-803
University of Utah
Phase 1 Withdrawn
NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT04290546 2026-02-27
CIML NK Cell in Head & Neck Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04898543 2025-12-11
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Active not recruiting
NCT01946789 2025-01-22
A Phase 1 Study of the Clinical and Immunologic Effects of ALT-803 in Patients With Advanced Solid Tumors
Altor BioScience
Phase 1 Completed
NCT02099539 2024-09-26
QUILT-3.005: A Study of N-803 in Patients With Relapsed or Refractory Multiple Myeloma
Altor BioScience
Phase 1 Terminated
NCT02890758 2023-02-21
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
Case Comprehensive Cancer Center
Phase 1 Completed
NCT02559674 2020-01-27
QUILT-2.001: ALT-803 in Patients With Advanced Pancreatic Cancer in Conjunction With Gemcitabine and Nab-Paclitaxel
Altor BioScience
Phase 1 Completed